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Tumorigenesis is a result of multiple mutational “as-
saults” on a cell that induce genetic instability and ul-
timately cause misregulation of components that are es-
sential for establishing a cellular-growth balance. The
genetic “hits” include the misregulation of gene tran-
scription—which affects growth-factor production and
expression of cytoplasmic and nuclear-signaling com-
ponents—as well as the loss or inactivation of DNA
repair enzymes and the abnormal regulation of growth-
factor receptors. As a result of these multiple defects,
the balance between cell growth and cell death is skewed
toward immortalization. Additional changes include the
acquisition of anchorage independence and the loss of
contact inhibition in cellular growth. Thus, the cells then
can proliferate continually, growing one on top of an-
other to produce a mass.
Further progression of the tumor cells from a benign
mass to a malignant tumor occurs when a single cell
obtains further genetic alterations affecting factors re-
sponsible for keeping the cell static. For example, some
of the known oncogenes (such as RAS and SRC) that
cause cell transformation also induce metastatic com-
petence (see Narod 1998 [in this issue]). Similarly, pro-
duction or activation of several serine, metalloaspartyl,
and thiol proteases supports the motility and invasion
of tumor cells through degradation of extracellular ma-
trix barriers (reviewed in Liotta et al. 1991; Steeg 1991).
Cells that accumulate such alterations then can invade
the surrounding tissue, an event that marks the begin-
ning of metastasis.
Metastasis is a principal cause of death of patients
diagnosed with solid malignant tumors. The metastatic
cascade has many facets linked in sequential steps: cells
must leave the primary tumor, invade the surrounding
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tissue, enter the circulatory or lymphatic system, ex-
travasate into a distant organ, stimulate angiogenesis,
and finally proliferate and flourish as a secondary colony
(reviewed in Liotta et al. 1991). Although tumor me-
tastasis must be measured in vivo by injecting tumor
cells into immunocompromised animals, aspects of the
process can be observed by means of a variety of cell-
culture techniques, such as assays for cell attachment,
motility, protease activity, invasion, colonization, and
angiogenesis (reviewed in Welch 1997).
As with other complex cascades, metastasis is con-
trolled, in part, through the induction and repression of
genes. To identify differentially expressed genes that
might be essential for metastasis, we performed differ-
ential colony hybridization on related murine melanoma
cells. From this study, we identified Nm23-H1 as an
mRNA species that accumulates at levels 10-fold higher
in cells with low metastatic activity than in their highly
metastatic counterparts, suggesting a role for this gene
in the metastatic progression (Steeg et al. 1988). More-
direct evidence that Nm23-H1 participates in—and pos-
sibly regulates—this process required a series of expres-
sion and transfection experiments. In multiple cohorts
of tumors, low Nm23-H1 protein and mRNA expres-
sion in the tumor specimens correlated with poor clinical
prognosis and survival, lymph node infiltration, and his-
topathological indicators of high metastatic potential.
This occurred in a variety of tumor types, including
breast, melanoma, gastric, and ovarian carcinomas (re-
viewed in De La Rosa et al. 1995). No mutations within
the coding region of Nm23-H1 were reported, suggest-
ing that expression of Nm23-H1, rather than its intrinsic
activity, was the limiting factor in metastatic cells. Ex-
periments in which Nm23-H1 cDNA was transfected
into melanoma and breast carcinoma cell lines confirmed
this conclusion. When transfectants were injected sub-
cutaneously or transplanted into the mammary fat pads
of nude mice, both the parental carcinoma cells, which
expressed Nm23-H1 at low levels, and the transfected
cells yielded primary tumors, but clones producing ex-
ogenous Nm23-H1 had a reduced potential for metas-
tasis (Leone et al. 1991a, 1993a). In addition, Nm23-
H1 overexpression specifically inhibited in vitro motility
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and colonization of metastatic cells, two key events in
the completion of the metastatic pathway (Leone et al.
1991a, 1993a). Thus, Nm23-H1 is not a tumor sup-
pressor but is a metastasis suppressor.
Mutations of Nm23
Whereas loss of Nm23-H1 expression predicts ag-
gressive metastatic growth of melanoma and mammary
carcinomas, aggressive neuroblastoma tumors at stages
III and IV exhibit elevated levels of Nm23-H1 RNA, a
predictor of poor patient survival (Leone et al. 1993b).
SSCP analysis of primary neuroblastoma tumors at dif-
ferent disease stages versus normal tissue identified a
lesion in the coding region of Nm23-H1 (Leone et al.
1993b; Chang et al. 1994). In several instances, this
point mutation, S120G, occurred as a somatic change
that is associated with advanced neuroblastoma but not
with earlier stage disease or with other kinds of tumors.
In one case, this same allele was found in the consti-
tutional tissue of a neuroblastoma patient and the pa-
tient’s father (Chang et al. 1994). Enhanced Nm23-H1
expression and amplification of one of the genomic al-
leles was observed only in advanced-stage cases (Leone
et al. 1993b). In general, however, cancers containing
overexpressed, mutated Nm23-H1 protein are rare
events, whereas loss of expression of Nm23-H1 is a com-
mon feature of aggressive, poorly differentiated tumors.
Genetics of NME1
NME1, the gene that encodes Nm23-H1, has been
mapped to 17q.21, a locus that is linked to familial early-
onset breast and ovarian cancer (Spurr et al. 1993) and
to the breast cancer suppressor geneBRCA1.RFLP anal-
ysis of human chromosomal DNA in the normal pop-
ulation identified two alleles, indicating the existence of
the two polymorphic variants of the gene (Leone et al.
1991b; Yague et al. 1991). Two independent investi-
gations for allelic deletions of NME1 in matched breast
normal and tumor tissues found that 20%–64% of het-
erozygous breast tumors exhibited deletion of one of two
polymorphic NME1 alleles (Leone et al. 1991b; Futreal
et al. 1992; Watatani et al. 1993). Allelic loss of NME1
also was reported for 42% of lung adenomas and 20%
of kidney carcinomas but was not detected in squamous
cell carcinomas, large cell carcinomas, and other ade-
nomas (Leone et al. 1991b). No association between this
loss of heterozygosity (LOH) and poor prognosis among
breast cancer survivors was detected (Cropp et al. 1994).
Most likely, deletions that lead to LOH for the BRCA1
gene account for the inconsistent deletion of NME1.
Nevertheless, reduced Nm23-H1 protein expression,
which was not predicted by LOH, was associated with
a poor prognosis (Cropp et al. 1994). Thus, we propose
that reduction of Nm23-H1 RNA and protein expres-
sion may result from RNA instability and/or an aber-
ration of transcription regulation, independent of LOH,
and that these regulatory events might be manipulated
to restore normal endogenous Nm23-H1 levels in highly
metastatic cells. As a step toward understanding the
mechanism(s) of differential Nm23-H1 expression oc-
curring between low and high metastatic cell types, we
have cloned a 2.1-kb promoter region of NME1 (De La
Rosa et al. 1996) and have begun to analyze the tran-
scriptional regulation of the gene.
Nm23-H1 in Differentiation and Development
Is the ability of Nm23-H1 to suppress both cell mo-
tility and colonization related to events that occur during
development? The first evidence to link Nm23-H1 to
normal development was reported for the Drosophila
homologue of NME1, abnormal wing discs (awd) (Biggs
et al. 1990). The original mutant allele, awdb3, was iden-
tified as a mutation that caused late larval/early pupal
lethality (reviewed in Timmons and Shearn 1997). Lar-
vae that are heterozygous for the awd mutation have
the same viability and developmental rate as wild-type
controls, whereas larvae homozygous for the mutation
stop growing and die in the middle of the third instar,
immediately before pupation. Developmental defects in
these third-instar–mutant larvae include morphologi-
cally abnormal and smaller wing discs and poorly dif-
ferentiated ovaries and eye antennae and leg discs, which
are larval tissues that normally develop into adult struc-
tures (Timmons and Shearn 1997). A null allele, awdKRs6,
caused similar but more severe developmental and mor-
phological defects, demonstrating that awd is essential
for development (Timmons and Shearn 1997). A third
awd mutant, awdkpn (referred to as “killer of prune”),
is a proline-to-serine point mutation that induces no ab-
errant phenotype, even in the homozygous state. How-
ever, the mutation is lethal in the background of a mu-
tation in a prune gene, indicating a functional interaction
between the two genes and possibly a physical interac-
tion between their products (Timmons and Shearn
1997).
Cellular differentiation is also strongly influenced by
Nm23-H1 in mammals. Howlett et al. (1994) grew cells
in a three-dimensional culture system, providing a base-
ment membrane that mimics the environment of the
mammary epithelium. This investigation showed that,
when a metastatic breast cancer cell line with low en-
dogenous Nm23-H1 expression was transfected with
Nm23-H1, the cells recovered their normal morphology
and patterns of growth (Howlett et al. 1994). Similarly,
Nm23-H1 cDNA, when transfected into human pheo-
chromocytoma cells, inhibited cellular proliferation and
initiated neurite differentiation in the presence of nerve
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growth factor (NGF), whereas downregulation of intra-
cellular Nm23-H1 stimulated cellular proliferation and
suppressed NGF-induced differentiation (Gervasi et al.
1996). Taken together, these genetic and cell-culture data
provide strong evidence linking the differentiation pro-
cess with Nm23-H1 protein levels.
Biochemical Activity of Nm23-H1/Mutational
Analysis
Through what mechanism does Nm23-H1 control cel-
lular differentiation and metastasis? Although there is
no clear answer to this question, the structure and bi-
ochemical features of Nm23-H1 provide some clues.
Nm23-H1 is a versatile kinase that can phosphorylate
nucleoside diphosphate molecules and histidine residues
on target proteins as well as autophosphorylate itself on
at least two specific serine residues. Its best-studied func-
tion is as a nucleoside diphosphate kinase (NDPK): it
transfers a terminal phosphate from a nucleoside tri-
phosphate (NTP) to a nucleoside diphosphate, through
a histidine-phosphate intermediate. The histidine phos-
phorylation occurs by autophosphorylation on histidine
residue 118 (on the human sequence). Although NTP
regeneration is required for both the energy needs of the
cell and for signal transduction by G-proteins, this bi-
ochemical activity does not appear to explain either the
metastatic suppressive nature of the protein or its role
in development (reviewed in Steeg and Wagner 1997;
also see below).
Just recently, we observed serine phosphorylation of
Nm23-H1 in immunoprecipitates from mammary epi-
thelial cell lysates (MacDonald et al. 1993). We detected
phosphorylation of two serine-containing peptides and
showed that these serine phosphorylations occurred
downstream from, and were dependent on, the forma-
tion of a histidine-phosphorylation intermediate, indi-
cating an autophosphorylation mechanism (MacDonald
et al. 1993; Freije et al. 1997). The significance of the
phosphate transfer from the histidine residue to the ser-
ine residue is still unknown, but this autophosphoryla-
tion possibly may regulate succeeding signaling events.
Site-directed mutagenesis experiments have allowed us
to start to uncouple the different biochemical activities
and biological functions. The Nm23-H1 mutants tested
include (1) a proline 96–to-serine change (P96S), which
is identical to the Drosophila mutation awdkpn; (2) a
serine 120–to-glycine substitution (S120G), which is
identical to the mutation found in very aggressive neu-
roblastomas; and (3) a serine 44–to-glycine change
(S44G), which removes a known phosphorylation site.
Single clones of breast carcinoma cells transfected with
mutant or wild-type Nm23-H1 cDNA were studied for
in vitro motility activity. In a Boyden chamber assay,
using serum or autotaxin as a stimulant, wild-type
Nm23-H1 completely abrogated any cell movement. In
contrast, the two mutants S120G and P96S reversed the
wild-type effect, whereas S44G closely resembled that
of the wild type (MacDonald et al. 1996). Thus, only
two known sites of the Nm23-H1 protein, P96 and
S120, were essential for its motility-suppression effect.
Purified, recombinant Nm23-H1 wild-type and mu-
tant proteins showed no significant differences in NDPK
activity or in serine and histidine autophosphorylation.
In contrast, histidine protein-kinase activity exhibited a
close correlation with the motility data: both P96S and
S120G mutants were kinase deficient (Freije et al. 1997).
Thus, the histidine kinase activity seems to act in a sig-
naling pathway that directs the cells to remain static.
These two mutations appear to alter the folding and
assembly of Nm23-H1 complexes and to decrease the
protein’s stability in response to denaturation by heat
and urea (Lascu et al. 1992, 1997; Chang et al. 1996).
Whether these folding differences explain the decreased
phosphotransfer of the proteins has yet to be determined,
but they may influence the recognition of substrate mol-
ecules or the stability of protein complexes.
Signal Transduction/Two-Component Relay System
The major biochemical effect that seems to be related
to motility behavior is the histidine protein-kinase ac-
tivity of Nm23, an activity that is well studied in pro-
karyotes. In general, kinases of this type transfer a phos-
phate from the histidine-phosphate intermediate to a
histidine or aspartate residue on an independent sub-
strate. In response to some environmental stimuli, these
proteins autophosphorylate on a histidine residue, ini-
tiating a series of phosphotransfer reactions. This relay
system is referred to as a two-component signaling path-
way. The autophosphorylated histidine protein kinase
transfers the phosphate from its own histidine to an
aspartate residue on a separate protein; this phosphate
is subsequently passed on to a histidine of another pro-
tein and then to an aspartate residue of the next protein
(reviewed in Appleby et al. 1996). In addition to pro-
karyotic systems, this ping-pong effect also has been de-
tected in eukaryotic systems such as yeast and the cel-
lular slime mold Dictyostelium discoideum. In yeast,
activation of an analogous signal transduction pathway
regulates activity of mitogen-activated protein kinases,
which control both growth and mating responses
(Maeda et al. 1994; Posas et al. 1996). Moreover, a
bacterial homologue of Nm23-H1 has been reported to
participate in a bacterial two-component system (Lu et
al. 1996). Finally, the wild-type Nm23-H1 phosphoryl-
ates an aspartate residue on a 43-kD protein found in
bovine brain-cell lysate, whereas the mutants P96S and
S120G do not (Wagner et al. 1997). These results suggest
that this phosphorelay system exists in mammalian cells
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and may be important in the suppression of cell motility
in premetastatic cells.
Summary
Nm23-H1 originally was discovered on the basis of
its reduced RNA expression in very highly metastatic
murine melanoma cell lines. Since that time, it has been
shown to reduce the metastatic potential of highly ag-
gressive tumors and to be an indicator of poor patient
prognosis in many cancer types. Although LOH of
NME1 is prevalent in many tumors, this event does not
predict reliably the overall levels of Nm23-H1 expres-
sion and therefore cannot be used as a genetic screen
for the aggressive potential of a cancer. In addition, mu-
tant forms of the gene exist; however, expression pat-
terns seem to be the key to the differences observed be-
tween tumor cells of high and low metastatic potential.
Differential Nm23-H1 expression may reflect transcrip-
tional regulation and/or the stability of the Nm23-H1
transcript. The mechanism of action of the protein is still
unknown; however, the protein does possess a unique
kinase activity that is essential in other organisms. The
histidine protein-kinase activity is the sole known activ-
ity that correlates tightly with the ability of Nm23-H1
to suppress cell motility. The identification of other com-
ponents comprising this signaling pathway will be the
next step toward unraveling the mysteries of this me-
tastasis suppressor.
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